Resistance to antimalarial drugs inevitably follows their deployment in malaria endemic parts of the world. For instance, current malaria control efforts which significantly rely on artemisinin combination therapies (ACTs) are being threatened by the emergence of resistance to artemisinins and ACTs. Understanding the role of genetic determinants of artemisinin resistance is therefore important for implementation of mitigation strategies. Moreover, elucidating the mode of action for drugs that are in advanced stages of development is specifically critical as drug resistance mechanisms can be prospectively predicted and possible means of surveillance put in place.
In the present work, CRISPR-Cas9 genome editing has been used to engineer candidate artemisinin resistance mutations (Kelch13 and UBP-1) in the rodent malaria parasite Plasmodium berghei. The role of these mutations in mediating artemisinin (and chloroquine) resistance under both in vitro and in vivo conditions has been assessed which up until now, has either remained un-validated (UBP-1) or debated (Kelch13, under in vivo conditions) in human infecting Plasmodium falciparum. The results have provided an in vivo model for understanding and validating artemisinin resistance phenotypes which just like their Plasmodium falciparum equivalents do not just mediate resistance phenotypes, but also carry accompanying fitness costs.
In addition to the above findings, biochemical and drug inhibition studies have been carried out to demonstrate that small molecule inhibitors targeting ubiquitin hydrolases (to which UBP-1 is a class member) display activity in human and rodent infecting malaria parasites in vitro and in vivo. These inhibitors also show evidence of ability to potentiate artemisinin action which can be exploited to overcome the emerging resistance as combination partner drugs. Untargeted metabolomic screens have also been used to characterize the mode of action of lead antimalarial drug candidates that are emerging from the Novartis Institute of Tropical Diseases drug discovery pipeline. A common biochemical and metabolic profile of these compounds which display a very fast parasite killing rate is presented and can hopefully be used to identify compounds that can achieve a similar feat. Moreover, these profiles have pointed to possible mode of action for novel drugs whose mechanistic mode of parasite killing is still unknown or disputed.
Item Type: | Thesis (PhD) |
---|---|
Qualification Level: | Doctoral |
Keywords: | Antimalarial drugs, mode of action, resistance, genetics models, biochemistry, metabolomics. |
Subjects: | > |
Colleges/Schools: | > > |
Funder's Name: | , |
Supervisor's Name: | Waters, Professor Andy and Barrett, Professor Mike |
Date of Award: | 2020 |
Depositing User: | |
Unique ID: | glathesis:2020-81876 |
Copyright: | Copyright of this thesis is held by the author. |
Date Deposited: | 17 Dec 2020 17:02 |
Last Modified: | 16 Sep 2022 15:52 |
Thesis DOI: | |
URI: |
View Item |
Downloads per month over past year
View more statistics
The University of Glasgow is a registered Scottish charity: Registration Number SC004401
IMAGES
VIDEO
COMMENTS
The management of malaria involves preventive and/or curative approaches. Since untreated uncomplicated malaria can progress to severe malaria, early diagnosis and effective rational treatment are the first core principles in the management of malaria.
Results: A marked increase of new malaria cases and incidence rate was observed in the 13 sentinel malaria notification sites in the locality (IR increased from 6.09 per 100,000 persondays in...
Malaria is a severe disease caused by parasites of the genus Plasmodium, which is transmitted to humans by a bite of an infected female mosquito of the species Anopheles. Malaria remains the leading cause of mortality around the world, and early diagnosis and fast-acting treatment prevent unwanted outcomes.
Malaria remains a major health challenge in Sub-Saharan Africa, despite extensive research. Several factors contribute to malaria transmission, including socio-ecological factors and changes in the human host and vector behavior, which may be channeled by parasite genetic changes.
A thesis submitted to the graduate faculty of Georgia State University in partial fulfillment of the requirements for the degree of Master of Public Health. Atlanta, GA 30303 Abstract. Background: Malaria in under-five children is a significant public health problem in sub-Saharan African countries with unprecedented mortality and morbidity.
Background:Malaria is Primarily a vector-borne disease caused by the protozoan Plasmodium. Protozoa Plasmodium is unicellular eukaryote parasites. These parasites are mostly transmitted to people through the bites of an infected Anopheles mosquito, called “malaria vectors.”
Background: Mortality due to severe malaria remains elevated in rural, high transmission areas despite more than a decade of control measures. Progression from uncomplicated to severe malaria is rapid, with death occurring within one to two days after symptom onset if no treatment is given.
exposes non-immune people to new malaria infections and creates new anti- genic combinations that continuously confound the immune systems of the more sessile existing residents of endemic sites.
Here we discuss the importance of human behaviour for malaria control programmes and provide an example of how behaviour change theory can be used to inform evidence-based social and behaviour change interventions.
Simwela, Nelson Victor (2020) Drug action and resistance in malaria parasites: experimental genetics models and biochemical features of fast acting novel antimalarials. PhD thesis, University of Glasgow. Full text available as: PDF.